HHS Public Access

Author manuscript

Neurobiol Dis. Author manuscript; available in PMC 2015 August 28.

Published in final edited form as:

Neurobiol Dis. 2010 June ; 38(3): 495–. doi:10.1016/j.nbd.2010.03.001.

Addendum to “Optimizing the success of cell transplantation therapy for stroke” [*Neurobiol Dis.* 37/2 (2010) 275–283]

Tonya M. Bliss*, Robert H. Andres, Gary K. Steinberg

Department of Neurosurgery and Stanford Stroke Center, Stanford University School of Medicine, Stanford, CA, USA

The authors have noted that data on two additional clinical trials involving stem cell therapy for stroke has become available since the article was published, and would like to have an addendum to the appropriate table. The addendum to the table appears below.

[Insert “Addendum to YNBDI 1994.doc” here]

DOI of original article: 10.1016/j.nbd.2009.10.003

*Corresponding author: +1 650 498 4134.

E-mail address: tbliss1@stanford.edu (T.M. Bliss)

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Addendum to Table 2

Current clinical cell transplantation trials for stroke

Two additional trials have been identified since publication of the manuscript

Clinical Identifier & Clinical phase	Cell Type	Estimated enrollment	Time of delivery*	Route of delivery	Country
NCT00761982 ^a Phase I/II	autologous bone marrow	20	5d–9d	intra-arterial	Spain
CTR1/2008/091/000046 ^b Phase II	autologous bone marrow	120	7d–30d	intravenous	India

Clinical identifier from

^aClinicaltrials.gov,

^bwww.ctri.in/ClinicalTrials

* time of delivery after stroke on-set